Abstract: Aim: Adjuvant therapy is not routinely recommended in stage II colon cancer, but may be considered for high-risk patients.
Introduction
Colorectal cancer is development of cancer in the colon or rectum. 1 It is due to abnormal growth of cells that have ability to invade or spread to other parts of body. 2 Globally , colorectal cancer is the third most common type of cancer making up about 10% of all cases.In 2012 there were 1.4 million new cases and 694,000 deaths from the disease.It is more common in developed countries, where more than 65% of cases are found. 3 Colorectal cancer 5-year survival rate is 80% to 90% for disease located in the intestinal wall, 40% to 60% for regional disease, and is less than 5% for metastatic disease. From all patients with colon cancer, the incidence of Stage II is from 40% to 45%; and 80% of patients with Stage II cancer colon are disease free after five years, admitted for surgical treatment with curative intention (standard treatment) and about 20% develop recurrence within the first five years. 4 Standard treatment for Stage II colon cancer is surgery with no adjuvant therapy; chemotherapy as adjuvant therapy is still controversial for clinical stage II but some series recommend complementary chemotherapy for patients with clinical pathological prognostic factors of recurrence. 5 In Stage III, chemotherapy as adjuvant treatment to surgery improved survival. 6 No remarkable additional benefit was observed in studies about Stage II, or Dukes B, colon cancer treated by surgery and adjuvant chemotherapy in relation to those treated only surgically. [6] [7] With the purpose of identifying what patients have greater risk of recurrence in Stage II colon cancer, clinical-pathological prognostic factors are evaluated that can predict recurrence [8] [9] [10] [11] [12] which could benefit from adjuvant chemotherapy.
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Patients and Methods
We conducted a non-experimental, longitudinal and retrospective clinical study of all patients admitted to One used the Chi-square test to establish the association between studied factors and recurrence, recurrence ratio was calculated by Kaplan -Meier method and Cox multivariate analysis was used for selecting prognostic factors for recurrence. Licensed Under Creative Commons Attribution CC BY surgery with curative intention, with a time interval from 2.5 months to 8.5 years. Eleven patients (5.5%) had localregional recurrence from 5 months to 6.7 years, and a mean time of recurrence of 2.4 years; among them six patients (3%) had local recurrence at the surgical table from 8 months to 4.6 years, and a mean time of recurrence of 2.3 years; and three patients (1.5%) had local recurrence in the anastomosis from 5 months to 6.7 years, and an average time of recurrence of 6.4 months. Five patients (2.5%) had pulmonary recurrence from 1 to 8.5 years, with a mean time of recurrence of 2.6 years. Two patients (1%) had hepatic recurrence in a 7-to 20-month interval, with a mean time of 14 months. Two patients (1%) had peritoneal recurrence from 2.5 months to 6.5 months, with a mean time of recurrence of 4.6 months ( Table 1) . Figure  1 ). Age did not have a significant association with the recurrence (p = 0.096) ( Table 2 ). 
Results

Location of recurrence in
Prognostic factors
Results show patients more than 70 years old have a significantly shorter disease-free time (p = 0.0305) ( Figure  2 ). No other factor turned out to be significant (Table 3 ). Cox regression showed that patients more than 70 years old have 2.56 times more risk of recurrence (Table 4) , that is, be more than 70 years is a factor determining recurrence. 
Discussion
World literature have few studies on risk factors for recurrence in Stage II colon cancer, and some take into consideration clinical findings such as type of presentation by emergency, be it by obstruction or perforation, site, CEA etc. and others consider pathological results such as histologic type, depth, differentiation, vascular and lymphatic invasion, etc. 8,10,12,14-15 demonstrating in some cases a certain relation with recurrence where a benefit would be gained from adjuvant treatment. [6] [7] In this study no evaluated factor had relation with this event, except age: patients more than 70 years old had a greater risk of recurrence, up to 2.56 times. In no study here mentioned was age a recurrence prognostic factor, and one would have to individualize patients according to their general clinical condition and comorbidity, analyzed the disadvantages and limitations of adjuvant treatment, since in our society average life expectancy is less than 70 years.
The incidence of Stage II colon cancer was compatible with world rates, around 40%, and recurrence percentage was 10%, half of the reported world average. 4 Nevertheless, around 30% of cases did not have the minimum follow-up time of two years; if we excluded patients about whom there is no certainty on their being disease free, the recurrence rate would rise to 15%.
In spite of the recommendations of ASCO, namely to consider the possibility of using adjuvant chemotherapy for patients who have as pathology results T4, lymphatic, vascular, or neural invasion, or else are operated due to perforation, less than 13 resected lymph nodes, this study demonstrated no statistical significance of these variables as regards recurrence.
Our study demonstrated that the most important prognostic factor for colon cancer is the presence of lymph nodes affected by the disease and that the main distant recurrences are the hepatic and the pulmonary one, but for patients with colon cancer without lymphnodes (Stage II), one has not data for pointing out the most important prognostic factors, and our study showed a local-regional recurrence rate of 5.5% from the 10% cases, and thus surgery plays for these patients a very important role. 18 Due to the great heterogeneity of Stage II colon tumors, the role of adjuvant chemotherapy is very controversial, since patient with tumors of the same clinical stage present different results, mainly related to recurrence. This way, the standard procedure is unable to exactly predict this neoplasia prognosis and makes necessary the identification of specific molecular characteristics of each tumor that can predict a better response to chemotherapy, intending to significantly reduce recurrence rates in Stage II. For identifying the groups of patients who can need adjuvant treatment, the correlation of molecular analysis and clinical data would be very helpful. The course of colon cancer, many genetic changes accumulate that frequently cause a kind of genomic instability. The two better known mechanisms of genomic instability are chromosomal instability (CIN) and microsatellite instability (MSI). CIN phenotype is found in about 85% of sporadic tumors and is characterized by aneuploidies, manifold chromosomal rearrangements and the accumulation of somatic mutations in K-RAS oncogene and in tumor-suppressor genes TP53 and APC. [16] [17] [18] MSI phenotype is associated with small insertions and deletions, mainly in repetitive sequences (microsatellite), and is found in approximately 15% of the cases. MSI is caused by defects in DNA repair system, including repair errors during DNA replication.
This instability is related to patients' prognosis and response to chemotherapy, 19 being frequently referred as highfrequency MSI (MSI-H). Diverse theories were postulated to explain why tumors with MSI-H present a better prognosis in spite of unfavorable histologic characteristics. One theory suggests that accumulation of genetic abnormalities causes aberrant protein expression, recognized by the immune system and triggering the destruction of tumor-like cells. Another theory relates the defect of the repair system to a better survival, since several mutations are not repaired during the replication and their accumulation becomes incompatible with cellular life.
Mutations in TP53 gene are associated to tumors aggressive growth and to reduced survival rates, whereas MSI-H seems to be related to a favorable prognosis of the disease. 16 Associations between somatic genetic alterations and the clinical behavior of colorectal tumors are rare.
Recent studies associated to tight-junction proteins key molecular components in cellular proliferation and neoplastic signaling, due to their double function of intracellular-extracellular signaling and cytoskeleton. Therefore, neoplastic cells show structural and functional deficiencies in "tight junction". Claudina-1, one of the proteins that comprise "tight junction", has a low expression in Stage II colorectal cancer and is a strong indicator of recurrence and poor survival for Stage II patients. 20 Another cellular-adhesion molecules involved in the progression of colorectal cancer is E-cadherin, which would help to identify sub-groups of high-risk patients which can need an appropriate and continuous therapeutic strategy. 21 Although this study intends to avoid adjuvant treatment for Stage II colon cancer patients submitted to surgical treatment with curative intention (an adequate oncologic operation), it is crucial to understand that colorectal cancer is a multiple-route disease that includes/understands clinical, pathological characteristics and molecular individuals and that the present idea of carcinogenesis routes simplification has been the main process negatively affecting the identification of risk factors for colorectal cancer. 22 Based on these molecular antecedents, the immunohistochemical study of TP53, K-RAS and APC, as well as the analysis of microsatellite instability and the sequencing of these genes in patients with Stage II colorectal cancer is suggested. 23, 24 
Conclusions
Five-year recurrence of patients curatively operated for Stage II colon adenocarcinoma in krishna hospital , karad from june 2005 to june 2015 has been 0.1257 with a standard deviation of 0.0294.
The only factor related to recurrence has been age: patients with more than 70 years at the time of the main surgery (p = 0.0305), had a risk of recurrence 2.56 times greater. No other studied factor has relation to recurrence. It is suggested molecular profile should be performed in stage II colon cancer patients. 
